دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In the Literature
Stan Deresinski
doi : 10.1093/cid/ciac836
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages i–ii
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials
Maria Garcia-Cremades, Katarina Vu�ićević, Craig W Hendrix, Priya Jayachandran, Leah Jarlsberg, Robert Grant, Connie L Celum, Michael Martin, Jared M Baeten, Jeanne Marrazzo, Peter Anderson, Kachit Choopanya, Suphak Vanichseni, David V Glidden, Radojka M Savic
doi : 10.1093/cid/ciac313
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1873–1882
Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent. The target protective plasma concentration of tenofovir (TFV), however, is not fully understood. The aim of this study is to estimate the protective TFV plasma concentration.
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, Haley Hedlin, Bryan Bunning, Katharine S Walter, Hector Bonilla, Athanasia Boumis, Michael Chen, Kimberly Clinton, Liisa Dewhurst, Carol Epstein, Prasanna Jagannathan, Richard H Kaszynski, Lori Panu, Julie Parsonnet, Elizabeth L Ponder, Orlando Quintero, Elizabeth Sefton, Upinder Singh, Luke Soberanis, Henry Truong, Jason R Andrews, Manisha Desai, Chaitan Khosla, Yvonne Maldonado
doi : 10.1093/cid/ciac312
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1883–1892
Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite limited data, favipiravir is administered to patients with coronavirus disease 2019 (COVID-19) in several countries.
Whole Blood Transfusion for Severe Malarial Anemia in a High Plasmodium falciparum Transmission Setting
Matthew M Ippolito, Jean-Bertin B Kabuya, Manuela Hauser, Luc K Kamavu, Proscovia Miiye Banda, Lisa R Yanek, Rubab Malik, Modest Mulenga, Jeffrey A Bailey, Gershom Chongwe, Thomas A Louis, Theresa A Shapiro, William J Moss, for the Southern and Central Africa International Centers of Excellence for Malaria Research
doi : 10.1093/cid/ciac304
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1893–1902
Severe malaria resulting from Plasmodium falciparum infection is the leading parasitic cause of death in children worldwide, and severe malarial anemia (SMA) is the most common clinical presentation. The evidence in support of current blood transfusion guidelines for patients with SMA is limited.
Multisystem Inflammatory Syndrome in Adults: Case Finding Through Systematic Review of Electronic Medical Records
Michael Melgar, Julia Haston, Jennifer DeCuir, Qi Cheng, Kathryn E Arnold, Lu Meng, David J Murphy, Elizabeth Overton, Julie Hollberg, Melissa Tobin-D’Angelo, Pragna Patel, Angela P Campbell, Shana Godfred-Cato, Ermias D Belay
doi : 10.1093/cid/ciac303
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1903–1911
Multisystem inflammatory syndrome in adults (MIS-A) is a severe condition temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Protective Effect of Intestinal Blautia Against Neutropenic Fever in Allogeneic Transplant Recipients
Armin Rashidi, Jonathan U Peled, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, LeeAnn T Marcello, Hossam Halaweish, Thomas Kaiser, Shernan G Holtan, Alexander Khoruts, Daniel J Weisdorf, Christopher Staley
doi : 10.1093/cid/ciac299
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1912–1920
Neutropenic fever (NF) occurs in >70% of hematopoietic cell transplant (HCT) recipients, without a documented cause in most cases. Antibiotics used to prevent and treat NF disrupt the gut microbiota; these disruptions predict a higher posttransplantation mortality rate. We hypothesized that specific features in the gut microbial community may mediate the risk of NF.
Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs
John A Staples, Meghan Ho, Dwight Ferris, Jan Hayek, Guiping Liu, Karen C Tran, Jason M Sutherland
doi : 10.1093/cid/ciac298
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1921–1929
Bacterial infections such as osteomyelitis and endocarditis routinely require several weeks of treatment with intravenous (IV) antimicrobials. Outpatient parenteral antimicrobial therapy (OPAT) programs allow patients to receive IV antimicrobials in an outpatient clinic or at home. The outcomes and costs of such treatments remain uncertain.
Epidemiology, Clinical Characteristics, and Outcomes of Influenza-Associated Hospitalizations in US Children Over 9 Seasons Following the 2009 H1N1 Pandemic
Satoshi Kamidani, Shikha Garg, Melissa A Rolfes, Angela P Campbell, Charisse N Cummings, Julia C Haston, Kyle P Openo, Emily Fawcett, Shua J Chai, Rachel Herlihy, Kimberly Yousey-Hindes, Maya L Monroe, Sue Kim, Ruth Lynfield, Chad Smelser, Alison Muse, Christina B Felsen, Laurie Billing, Ann Thomas, H Keipp Talbot, William Schaffner, Ilene Risk, Evan J Anderson
doi : 10.1093/cid/ciac296
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1930–1939
Recent population-based data are limited regarding influenza-associated hospitalizations in US children.
US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response
Jasmine T Plummer, Deisy Contreras, Wenjuan Zhang, Aleksandra Binek, Ruan Zhang, Felipe Dezem, Stephanie S Chen, Brian D Davis, Jorge Sincuir Martinez, Aleksandr Stotland, Simion Kreimer, Elias Makhoul, Saleh Heneidi, Celeste Eno, Bongha Shin, Anders H Berg, Susan Cheng, CORALE Study Group, Stanley C Jordan, Eric Vail, Jennifer E Van Eyk, Margie A Morgan
doi : 10.1093/cid/ciac295
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1940–1949
The multiple mutations comprising the epsilon variant demonstrate the independent convergent evolution of severe acute respiratory syndrome coronavirus (SARS-CoV-2), with its spike protein mutation L452R present in the delta (L452R), kappa (L452R), and lambda (L452Q) variants.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Pregnancy in Sub-Saharan Africa: A 6-Country Retrospective Cohort Analysis
Jean B Nachega, Nadia A Sam-Agudu, Rhoderick N Machekano, Philip J Rosenthal, Sonja Schell, Liesl de Waard, Adrie Bekker, Onesmus W Gachuno, John Kinuthia, Nancy Mwongeli, Samantha Budhram, Valerie Vannevel, Priya Somapillay, Hans W Prozesky, Jantjie Taljaard, Arifa Parker, Elizabeth Agyare, Akwasi Baafuor Opoku, Aminatu Umar Makarfi, Asara M Abdullahi, Chibueze Adirieje, Daniel Katuashi Ishoso, Michel Tshiasuma Pipo, Marc B Tshilanda, Christian Bongo-Pasi Nswe, John Ditekemena, Lovemore Nyasha Sigwadhi, Peter S Nyasulu, Michel P Hermans, Musa Sekikubo, Philippa Musoke, Christopher Nsereko, Evans K Agbeno, Michael Yaw Yeboah, Lawal W Umar, Mukanire Ntakwinja, Denis M Mukwege, Etienne Kajibwami Birindwa, Serge Zigabe Mushamuka, Emily R Smith, Edward J Mills, John Otokoye Otshudiema, Placide Mbala-Kingebeni, Jean-Jacques Muyembe Tamfum, Alimuddin Zumla, Aster Tsegaye, Alfred Mteta, Nelson K Sewankambo, Fatima Suleman, Prisca Adejumo, Jean R Anderson, Emilia V Noormahomed, Richard J Deckelbaum, Jeffrey S A Stringer, Abdon Mukalay, Taha E Taha, Mary Glenn Fowler, Judith N Wasserheit, Refiloe Masekela, John W Mellors, Mark J Siedner, Landon Myer, Andre-Pascal Kengne, Marcel Yotebieng, Lynne M Mofenson, Eduard Langenegger, for the AFREhealth Research Collaboration on COVID-19 and Pregnancy
doi : 10.1093/cid/ciac294
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1950–1961
Few data are available on COVID-19 outcomes among pregnant women in sub-Saharan Africa (SSA), where high-risk comorbidities are prevalent. We investigated the impact of pregnancy on SARS-CoV-2 infection and of SARS-CoV-2 infection on pregnancy to generate evidence for health policy and clinical practice.
β-Lactam–Resistant Streptococcus pneumoniae Dynamics Following Treatment: A Dose-Response Meta-analysis
Matas Griskaitis, Luis Furuya-Kanamori, Kasim Allel, Richard Stabler, Patrick Harris, David L Paterson, Laith Yakob
doi : 10.1093/cid/ciac293
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1962–1970
Patient exposure to antibiotics promotes the emergence of drug-resistant pathogens. The aim of this study was to identify whether the temporal dynamics of resistance emergence at the individual-patient level were predictable for specific pathogen-drug classes.
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Kazuya Suami, Ai Yagiuchi, Yuya Kimura, Masaru Komino, Hiromi Arai, Toru Morikawa, Iori Motohashi, Rei Miyazawa, Tetsu Moriyama, Hiroshi Kamura, Mayumi Terada, Osamu Kuwamitsu, Tomoichiro Hayakawa, Eiichiro Sando, Yasuji Ohara, Osamu Teshigahara, Motoi Suzuki, Konosuke Morimoto
doi : 10.1093/cid/ciac292
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1971–1979
Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant.
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
Danuta M Skowronski, Yossi Febriani, Manale Ouakki, Solmaz Setayeshgar, Shiraz El Adam, Macy Zou, Denis Talbot, Natalie Prystajecky, John R Tyson, Rodica Gilca, Nicholas Brousseau, Geneviève Deceuninck, Eleni Galanis, Chris D Fjell, Hind Sbihi, Elise Fortin, Sapha Barkati, Chantal Sauvageau, Monika Naus, David M Patrick, Bonnie Henry, Linda M N Hoang, Philippe De Wals, Christophe Garenc, Alex Carignan, Mélanie Drolet, Agatha N Jassem, Manish Sadarangani, Marc Brisson, Mel Krajden, Gaston De Serres
doi : 10.1093/cid/ciac290
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1980–1992
The Canadian coronavirus disease 2019 (COVID-19) immunization strategy deferred second doses and allowed mixed schedules. We compared 2-dose vaccine effectiveness (VE) by vaccine type (mRNA and/or ChAdOx1), interval between doses, and time since second dose in 2 of Canada’s larger provinces.
Anal Human Papillomavirus Infection in Kidney Transplant Recipients Compared With Immunocompetent Controls
Helle Kiellberg Larsen, Susanne K Kjaer, Merete Haedersdal, Alexander K Kjaer, Jesper Hansen Bonde, Søren Schwartz Sørensen, Louise T Thomsen
doi : 10.1093/cid/ciac285
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1993–1999
Kidney transplant recipients (KTRs) have increased risk of human papillomavirus (HPV)–related anogenital (pre)cancers, including anal high-grade intraepithelial lesions and cancer. Previous studies on anal high-risk HPV (hrHPV) among KTRs are sparse.
Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial
Rubina Bunjun, Tanko F Ramla, Shameem Z Jaumdally, Laura Noël-Romas, Hossaena Ayele, Bryan P Brown, Hoyam Gamieldien, Rushil Harryparsad, Smritee Dabee, Gonasagrie Nair, Maricianah Onono, Thesla Palanee-Phillips, Catilin W Scoville, Kate B Heller, Jared M Baeten, Steven E Bosinger, Adam Burgener, Jo-Ann S Passmore, Heather Jaspan, Renee Heffron
doi : 10.1093/cid/ciac284
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2000–2011
Cervicovaginal CD4+ T cells are preferential targets for human immunodeficiency virus (HIV) infection and have consequently been used as a proxy measure for HIV susceptibility. The ECHO randomized trial offered a unique opportunity to consider the association between contraceptives and Th17-like cells within a trial designed to evaluate HIV risk.
Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide
SofÃa Scévola, Arkaitz Imaz, Mackenzie L Cottrell, Jordi Niubo, Brian Van Horne, Juan Tiraboschi, Maria Saumoy, Sandra Morenilla, Irene Soriano, Angela D M Kashuba, Daniel Podzamczer
doi : 10.1093/cid/ciac410
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2012–2015
Doravirine (DOR) concentrations and HIV-1 RNA were evaluated in genital fluids from adults with HIV on stable therapy who switched to DOR + FTC/TAF. High protein-unbound DOR concentrations were observed in both seminal plasma and cervicovaginal fluid. DOR + FTC/TAF maintained viral suppression in genital fluids in all but 1 participant.
Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus-1 Disease
Anna C Riddell, Beatrix Kele, Kathryn Harris, Jon Bible, Maurice Murphy, Subathira Dakshina, Nathaniel Storey, Dola Owoyemi, Corinna Pade, Joseph M Gibbons, David Harrington, Eliza Alexander, �ine McKnight, Teresa Cutino-Moguel
doi : 10.1093/cid/ciac409
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2016–2018
The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is of public health concern in case of vaccine escape. Described are 3 patients with advanced human immunodeficiency virus (HIV)-1 and chronic SARS-CoV-2 infection in whom there is evidence of selection and persistence of novel mutations that are associated with increased transmissibility and immune escape.
Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection
Carolyn D Alonso, Nira R Pollock, Kevin W Garey, Anne J Gonzales-Luna, David N Williams, Kaitlyn Daugherty, Christine Cuddemi, Javier Villafuerte-Gálvez, Nicole C White, Xinhua Chen, Hua Xu, Rebecca Sprague, Caitlin Barrett, Mark Miller, Agnès Foussadier, Aude Lantz, Alice Banz, Ciarán P Kelly
doi : 10.1093/cid/ciac406
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2019–2022
Ultrasensitive, quantitative Clostridioides difficile stool toxin measurement demonstrated significantly higher concentrations of toxins A and B in patients infected with the North American pulsed-field gel electrophoresis type 1/ribotype 027 (NAP-1/027) strain compared with other strains, providing in vivo confirmation of the in vitro association between NAP-1/027 and elevated toxin production.
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination
Amihai Rottenstreich, Olesya Vorontsov, Or Alfi, Gila Zarbiv, Esther Oiknine-Djian, Roy Zigron, Geffen Kleinstern, Michal Mandelboim, Shay Porat, Dana G Wolf
doi : 10.1093/cid/ciac395
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2023–2026
We evaluated the neutralization efficiency against SARS-CoV-2 Omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against Omicron were lacking at the time of delivery after 2-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against Omicron among mothers and neonates.
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
Steven Y C Tong, Jocelyn Mora, Asha C Bowen, Matthew P Cheng, Nick Daneman, Anna L Goodman, George S Heriot, Todd C Lee, Roger J Lewis, David C Lye, Robert K Mahar, Julie Marsh, Anna McGlothlin, Zoe McQuilten, Susan C Morpeth, David L Paterson, David J Price, Jason A Roberts, J Owen Robinson, Sebastiaan J van Hal, Genevieve Walls, Steve A Webb, Lyn Whiteway, Dafna Yahav, Joshua S Davis, for the Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group
doi : 10.1093/cid/ciac476
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2027–2034
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection.
Unilateral Lower Extremity Elephantiasis
Xi Duan, Xincai Xiong, Hai Yu, Liehua Deng
doi : 10.1093/cid/ciac251
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2035–2037
Harnessing the Power of Health Systems and Networks for Antimicrobial Stewardship
HEALTHCARE EPIDEMOLOGY: Robert Weinstein, Whitney R Buckel, Edward A Stenehjem, Adam L Hersh, David Y Hyun, Rachel M Zetts
doi : 10.1093/cid/ciac515
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2038–2044
Twenty of 21 health systems and network-based antimicrobial stewardship programs (ASPs) who were invited participated in a questionnaire, a webinar, and focus groups to understand implementation strategies for system-wide antimicrobial stewardship.
Pharyngeal Chlamydia trachomatis in Men Who Have Sex With Men in a Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Program in Hanoi, Vietnam
Hao T M Bui, Paul C Adamson, Giang M Le, Jeffrey D Klausner
doi : 10.1093/cid/ciac618
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2045–2046
BK Polyomavirus Consensus
Hans H Hirsch, Michael Mengel, Nassim Kamar
doi : 10.1093/cid/ciac594
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2046–2047
Reply to Author
Hannah Imlay, Aimee C Hodowanec, Takashi E Komatsu, Jules O’Rear, Andreas Pikis, Ajit P Limaye
doi : 10.1093/cid/ciac678
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2047–2048
Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients
Bryan Pesko, Alexandra Deng, Jeannie D Chan, Santiago Neme, Shireesha Dhanireddy, Rupali Jain
doi : 10.1093/cid/ciac588
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 2049–2050
Reply to Pesko et al
Ronza Najjar-Debbiny, Naomi Gronich, Gabriel Weber, Johad Khoury, Lee Hilary Goldstein, Walid Saliba
doi : 10.1093/cid/ciac589
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Page 2050
Correction to: Herpes Simplex Virus 2 Meningitis in Adults: A Prospective, Nationwide, Population-Based Cohort Study
doi : 10.1093/cid/ciac790
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Page 2051
Correction for CID-113796 – ciac440
doi : 10.1093/cid/ciac844
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Page 2051
Correction to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America
doi : 10.1093/cid/ciac474
Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Page 2052
